Alphatec Holdings, Inc. - Common Stock (ATEC)

Surgical hardware surged 17% as surgeon adoption hit record levels, offsetting biologics weakness.

Alphatec (NASDAQ:ATEC) reported third-quarter revenue growth and expanded profitability, while lowering its full-year outlook to reflect weaker biologics performance, softer thoracolumbar procedure volumes and a temporary international supply constraint. Revenue for the third quarter totaled $221 m

Patrick's purchase brings his total beneficial ownership to 6.2 million shares worth $54.41 million, signaling confidence despite the stock's 42% decline over the past year.

Surgical case volume surged 20% as EOS Insight adoption accelerated.

Alphatec (NASDAQ:ATEC) reported second-quarter 2026 revenue of $214 million, up 15% from a year earlier, as growth in surgical procedures and surgeon adoption supported higher profitability and positive free cash flow. Chairman and CEO Pat Miles said surgical revenue rose 17% to $196 million, while

Alphatec bets on integrated spine surgery tech, while Inspire leads in sleep apnea devices with robust profitability. How do their financials and risks stack up?

This medical technology company delivers advanced spinal surgery devices and biologics to U.S. hospitals and healthcare providers.

This medical technology firm provides spinal surgery solutions to U.S. hospitals and surgical centers through proprietary devices.

Alphatec (ATEC) Q1 2026 Earnings Transcript

See how a prediction markets trading strategy helps traders anticipate earnings moves and capitalize on pricing gaps.

This spine surgery innovator reported a notable insider sale amid a year of strong share performance.

This spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.

Learn how this earnings trading strategy turns quarterly market volatility storms into structured opportunity.